Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Publikationen

Suchbegriffe: IMMUNE CHECKPOINT INHIBITORS, . Treffer: 27

2022

Barth, DA; Stanzer, S; Spiegelberg, JA; Bauernhofer, T; Absenger, G; Szkandera, J; Gerger, A; Smolle, MA; Hutterer, GC; Ahyai, SA; Madl, T; Posch, F; Riedl, JM; Klec, C; Jost, PJ; Kargl, J; Stradner, MH; Pichler, M Patterns of Peripheral Blood B-Cell Subtypes Are Associated With Treatment Response in Patients Treated With Immune Checkpoint Inhibitors: A Prospective Longitudinal Pan-Cancer Study.
Front Immunol. 2022; 13: 840207 Doi: 10.3389/fimmu.2022.840207 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

Bergler-Klein, J; Rainer, PP; Wallner, M; Zaruba, MM; Dörler, J; Böhmer, A; Buchacher, T; Frey, M; Adlbrecht, C; Bartsch, R; Gyöngyösi, M; Fürst, UM Cardio-oncology in Austria: cardiotoxicity and surveillance of anti-cancer therapies : Position paper of the Heart Failure Working Group of the Austrian Society of Cardiology.
Wien Klin Wochenschr. 2022; 134(17-18):654-674 Doi: 10.1007/s00508-022-02031-0 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

Moik, F; Ay, C Venous and arterial thromboembolism in patients with cancer treated with targeted anti-cancer therapies
THROMB RES. 2022; 213: S58-S65. Doi: 10.1016/j.thromres.2022.01.004
Web of Science PubMed FullText FullText_MUG

 

2021

Aureli, A; Marziani, B; Sconocchia, T; Del, Principe, MI; Buzzatti, E; Pasqualone, G; Venditti, A; Sconocchia, G Immunotherapy as a Turning Point in the Treatment of Acute Myeloid Leukemia.
Cancers (Basel). 2021; 13(24): Doi: 10.3390/cancers13246246 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

Brcic, L; Mathilakathu, A; Walter, RFH; Wessolly, M; Mairinger, E; Beckert, H; Kreidt, D; Steinborn, J; Hager, T; Christoph, DC; Kollmeier, J; Mairinger, T; Wohlschlaeger, J; Schmid, KW; Borchert, S; Mairinger, FD Digital Gene Expression Analysis of Epithelioid and Sarcomatoid Mesothelioma Reveals Differences in Immunogenicity.
Cancers (Basel). 2021; 13(8): Doi: 10.3390/cancers13081761 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

Geiger-Gritsch, S; Olschewski, H; Kocher, F; Wurm, R; Absenger, G; Flicker, M; Hermann, A; Heininger, P; Fiegl, M; Zechmeister, M; Endel, F; Wild, C; Pall, G Real-world experience with anti-PD-1/PD-L1 monotherapy in patients with non-small cell lung cancer : A retrospective Austrian multicenter study.
Wien Klin Wochenschr. 2021; 133(21-22):1122-1130 Doi: 10.1007/s00508-021-01940-w
Web of Science PubMed FullText FullText_MUG

 

Jabkowski, J; Loidl, A; Auinger, B; Kehrer, H; Sepp, N; Pichler, R Pembrolizumab-Induced Thyroiditis Shows PD-L1Expressing Histiocytes and Infiltrating T Cells in Thyroid Tissue - A Case Report.
Front Immunol. 2021; 12: 606056 Doi: 10.3389/fimmu.2021.606056 (- Case Report) [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

Kaiser, M; Semeraro, MD; Herrmann, M; Absenger, G; Gerger, A; Renner, W Immune Aging and Immunotherapy in Cancer.
Int J Mol Sci. 2021; 22(13): 7016 Doi: 10.3390/ijms22137016 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

Moik, F; Chan, WE; Wiedemann, S; Hoeller, C; Tuchmann, F; Aretin, MB; Fuereder, T; Zöchbauer-Müller, S; Preusser, M; Pabinger, I; Ay, C Incidence, risk factors, and outcomes of venous and arterial thromboembolism in immune checkpoint inhibitor therapy.
Blood. 2021; 137(12):1669-1678 Doi: 10.1182/blood.2020007878 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

Pichler, M; Steyrer, J Cost-effectiveness analysis of the use of immunotherapy in metastatic solid tumours in Austria by applying the ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) version 1.1.
ESMO Open. 2021; 6(4): 100198 Doi: 10.1016/j.esmoop.2021.100198 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

Pink, D; Andreou, D; Bauer, S; Brodowicz, T; Kasper, B; Reichardt, P; Richter, S; Lindner, LH; Szkandera, J; Gruenwald, V; Kebenko, M; Kirchner, M; Hohenberger, P Treatment of Angiosarcoma with Pazopanib and Paclitaxel: Results of the EVA (Evaluation of Votrient(R) in Angiosarcoma) Phase II Trial of the German Interdisciplinary Sarcoma Group (GISG-06)
CANCERS. 2021; 13(6): 1223 Doi: 10.3390/cancers13061223 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

Semrau, S; Gostian, AO; Traxdorf, M; Eckstein, M; Rutzner, S; von, der, Grün, J; Illmer, T; Hautmann, M; Klautke, G; Laban, S; Brunner, T; Tamaskovics, B; Frey, B; Zhou, JG; Geppert, CI; Hartmann, A; Balermpas, P; Budach, W; Gaipl, U; Iro, H; Fietkau, R; Hecht, M Implementation of Double Immune Checkpoint Blockade Increases Response Rate to Induction Chemotherapy in Head and Neck Cancer.
Cancers (Basel). 2021; 13(8): Doi: 10.3390/cancers13081959 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

Walsh, NM; Cerroni, L Merkel cell carcinoma: A review.
J Cutan Pathol. 2021; 48(3):411-421 Doi: 10.1111/cup.13910 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Weber, S; van der Leest, P; Donker, HC; Schlange, T; Timens, W; Tamminga, M; Hasenleithner, SO; Graf, R; Moser, T; Spiegl, B; Yaspo, ML; Terstappen, LWMM; Sidorenkov, G; Hiltermann, TJN; Speicher, MR; Schuuring, E; Heitzer, E; Groen, HJM Dynamic Changes of Circulating Tumor DNA Predict Clinical Outcome in Patients With Advanced Non-Small-Cell Lung Cancer Treated With Immune Checkpoint Inhibitors
JCO PRECIS ONCOL. 2021; 5: 1540-1553. Doi: 10.1200/PO.21.00182
Web of Science PubMed FullText FullText_MUG

 

Zhou, Y; Bastian, IN; Long, MD; Dow, M; Li, W; Liu, T; Ngu, RK; Antonucci, L; Huang, JY; Phung, QT; Zhao, XH; Banerjee, S; Lin, XJ; Wang, H; Dang, B; Choi, S; Karin, D; Su, H; Ellisman, MH; Jamieson, C; Bosenberg, M; Cheng, Z; Haybaeck, J; Kenner, L; Fisch, KM; Bourgon, R; Hernandez, G; Lill, JR; Liu, S; Carter, H; Mellman, I; Karin, M; Shalapour, S Activation of NF-κB and p300/CBP potentiates cancer chemoimmunotherapy through induction of MHC-I antigen presentation.
Proc Natl Acad Sci U S A. 2021; 118(8): Doi: 10.1073/pnas.2025840118 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

2020

Riedl, JM; Barth, DA; Brueckl, WM; Zeitler, G; Foris, V; Mollnar, S; Stotz, M; Rossmann, CH; Terbuch, A; Balic, M; Niedrist, T; Bertsch, T; Stoeger, H; Pichler, M; Olschewski, H; Absenger, G; Ficker, JH; Gerger, A; Posch, F C-Reactive Protein (CRP) Levels in Immune Checkpoint Inhibitor Response and Progression in Advanced Non-Small Cell Lung Cancer: A Bi-Center Study.
Cancers (Basel). 2020; 12(8): Doi: 10.3390/cancers12082319 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

Smolle, E; Leithner, K; Olschewski, H Oncogene addiction and tumor mutational burden in non-small-cell lung cancer: Clinical significance and limitations.
Thorac Cancer. 2020; 11(2):205-215 Doi: 10.1111/1759-7714.13246 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

Smolle, MA; Szkandera, J; Andreou, D; Palmerini, E; Bergovec, M; Leithner, A Treatment options in unresectable soft tissue and bone sarcoma of the extremities and pelvis - a systematic literature review.
EFORT Open Rev. 2020; 5(11):799-814 Doi: 10.1302/2058-5241.5.200069 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

Theiler-Schwetz, V; Trummer, C; Richtig, E; Richtig, G; Pilz, S Thyroid disorders during immune checkpoint inhibitor therapy.
AUST J CLIN ENDOCR M. 2020; Doi: 10.1007/s41969-020-00111-y [OPEN ACCESS]
Web of Science FullText FullText_MUG

 

2019

Smolle, MA; Prinz, F; Calin, GA; Pichler, M Current concepts of non-coding RNA regulation of immune checkpoints in cancer.
Mol Aspects Med. 2019; 70:117-126 Doi: 10.1016/j.mam.2019.09.007
Web of Science PubMed FullText FullText_MUG

 

Weide, B; Eigentler, T; Catania, C; Ascierto, PA; Cascinu, S; Becker, JC; Hauschild, A; Romanini, A; Danielli, R; Dummer, R; Trefzer, U; Elia, G; Neri, D; Garbe, C A phase II study of the L19IL2 immunocytokine in combination with dacarbazine in advanced metastatic melanoma patients.
Cancer Immunol Immunother. 2019; 68(9):1547-1559 Doi: 10.1007/s00262-019-02383-z
Web of Science PubMed FullText FullText_MUG

 

2018

Leitinger, M; Varosanec, MV; Pikija, S; Wass, RE; Bandke, D; Weis, S; Studnicka, M; Grinzinger, S; McCoy, MR; Hauer, L; Sellner, J Fatal Necrotizing Encephalopathy after Treatment with Nivolumab for Squamous Non-Small Cell Lung Cancer: Case Report and Review of the Literature.
Front Immunol. 2018; 9(1): 108-108. Doi: 10.3389/fimmu.2018.00108 (- Case Report) [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

Mark, NM; Kargl, J; Busch, SE; Yang, GHY; Metz, HE; Zhang, H; Hubbard, JJ; Pipavath, SNJ; Madtes, DK; Houghton, AM Chronic Obstructive Pulmonary Disease Alters Immune Cell Composition and Immune Checkpoint Inhibitor Efficacy in Non-Small Cell Lung Cancer.
Am J Respir Crit Care Med. 2018; 197(3):325-336 Doi: 10.1164/rccm.201704-0795OC [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

2017

Hendry, S; Salgado, R; Gevaert, T; Russell, PA; John, T; Thapa, B; Christie, M; van de Vijver, K; Estrada, MV; Gonzalez-Ericsson, PI; Sanders, M; Solomon, B; Solinas, C; Van den Eynden, GGGM; Allory, Y; Preusser, M; Hainfellner, J; Pruneri, G; Vingiani, A; Demaria, S; Symmans, F; Nuciforo, P; Comerma, L; Thompson, EA; Lakhani, S; Kim, SR; Schnitt, S; Colpaert, C; Sotiriou, C; Scherer, SJ; Ignatiadis, M; Badve, S; Pierce, RH; Viale, G; Sirtaine, N; Penault-Llorca, F; Sugie, T; Fineberg, S; Paik, S; Srinivasan, A; Richardson, A; Wang, YH; Chmielik, E; Brock, J; Johnson, DB; Balko, J; Wienert, S; Bossuyt, V; Michiels, S; Ternes, N; Burchardi, N; Luen, SJ; Savas, P; Klauschen, F; Watson, PH; Nelson, BH; Criscitiello, C; O'Toole, S; Larsimont, D; de Wind, R; Curigliano, G; Andre, F; Lacroix-Triki, M; van de Vijver, M; Rojo, F; Floris, G; Bedri, S; Sparano, J; Rimm, D; Nielsen, T; Kos, Z; Hewitt, S; Singh, B; Farshid, G; Loibl, S; Allison, KH; Tung, N; Adams, S; Willard-Gallo, K; Horlings, HM; Gandhi, L; Moreira, A; Hirsch, F; Dieci, MV; Urbanowicz, M; Brcic, I; Korski, K; Gaire, F; Koeppen, H; Lo, A; Giltnane, J; Rebelatto, MC; Steele, KE; Zha, JP; Emancipator, K; Juco, JW; Denkert, C; Reis, J; Loi, S; Fox, SB Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further Research
ADV ANAT PATHOL. 2017; 24(5): 235-251. Doi: 10.1097/PAP.0000000000000162 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

Zaric, B; Brcic, L; Buder, A; Tomuta, C; Brandstetter, A; Buresch, J; Traint, S; Stojsic, V; Kovacevic, T; Perin, B; Pirker, R; Filipits, M PD-1 Protein Expression Predicts Survival in Resected Adenocarcinomas of the Lung
J THORAC ONCOL. 2017; 12(1):S981-S981.-IASLC 17th World Conference on Lung Cancer; DEC 4-7, 2016; Vienna, AUSTRIA . Doi: 10.1016/j.jtho.2016.11.1357 [Poster]
Web of Science FullText FullText_MUG

 

2016

Richtig, G; Aigelsreiter, A; Kashofer, K; Talakic, E; Kupsa, R; Schaider, H; Richtig, E Two Case Reports of Rare BRAF Mutations in Exon 11 and Exon 15 with Discussion of Potential Treatment Options.
Case Rep Oncol. 2016; 9(3):543-546 Doi: 10.1159/000449125 (- Case Report) [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

Woltsche, N; Schwab, C; Deinlein, T; Hofmann-Wellenhof, R; Zalaudek, I Dermoscopy in the era of dermato-oncology: from bed to bench side and retour.
Expert Rev Anticancer Ther. 2016; 16(5):531-541 Doi: 10.1586/14737140.2016.1168700
Web of Science PubMed FullText FullText_MUG

 

↑ Seitenanfang / Navigation

© Med Uni Graz • Impressum